On October 1, 2025, KalVista Pharmaceuticals appointed Bethany Sensenig to its Board and Audit Committee, with compensation including options for 45,000 shares and a cash retainer of $42,500. Additionally, at the same meeting, two Class I directors were elected, and Deloitte & Touche LLP was ratified as the independent accounting firm for the next transition period.